M1 Kliniken (M12) H2 2025 earnings summary

Executive summary

• Achieved strong growth in EBIT (+29.2%) and earnings per share (+40%) for FY 2025, driven by operational efficiency and expanded medical capacities.

• Continued profitable growth trajectory with increased revenue and improved margins.

Financial highlights

• Group revenue rose 7.4% year-over-year to €364.3 million.

• EBITDA increased 23.6% to €39.4 million; EBIT up 29.2% to €34.6 million.

• EBIT margin improved to 9.5% from 7.9% in the prior year.

• Earnings per share climbed to €1.19 from €0.85 year-over-year.

Outlook and guidance

• Plans to expand national and international clinics to sustain profitable growth.

• Beauty segment targets €200–300 million revenue by 2029 with at least 20% EBIT margin.

• Aims to establish the brand as the global leader in aesthetic medicine.